{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:03:57Z","timestamp":1780455837079,"version":"3.54.1"},"reference-count":46,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T00:00:00Z","timestamp":1692057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bayer AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>An increased risk of non-pathological fractures in patients with prostate cancer and bone metastases has been associated with combination treatment with radium-223, abiraterone, and prednisone\/prednisolone in the absence of bone-protecting agents. Here, we investigated possible mechanisms leading to this outcome using an intratibial LNCaP model mimicking prostate cancer bone metastases. Male NOD.scid mice were inoculated intratibially with LNCaP prostate cancer cells and treated with vehicle, radium-223, abiraterone, prednisone, zoledronic acid, or their combinations for 28 days. Serum TRACP 5b and PSA levels were measured. Bone structure, quality, and formation rate of non-tumor-bearing and tumor-bearing tibiae were analyzed by microCT, 3-point bending assay, and dynamic histomorphometry, respectively. Radium-223 incorporation into bone was also measured. Radium-223\/abiraterone\/prednisone combination treatment induced a transient increase in bone resorption indicated by elevated TRACP 5b levels, which was inhibited by concurrent treatment with zoledronic acid. Furthermore, radium-223\/abiraterone\/prednisone combination reduced periosteal and trabecular new bone formation and the number of osteoblasts, but bone structure or biomechanical quality were not affected. The abiraterone\/prednisone treatment decreased radium-223 incorporation into tumor-bearing bone, possibly explaining the lack of additional antitumor efficacy. In conclusion, radium-223\/abiraterone\/prednisone combination increased bone resorption, which may have been one of the mechanisms leading to an increased fracture risk in patients with mCRPC.<\/jats:p>","DOI":"10.3390\/cancers15164115","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T11:09:44Z","timestamp":1692097784000},"page":"4115","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Zoledronic Acid Prevents Bone Resorption Caused by the Combination of Radium-223, Abiraterone Acetate, and Prednisone in an Intratibial Prostate Cancer Mouse Model"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-6595","authenticated-orcid":false,"given":"Mari I.","family":"Suominen","sequence":"first","affiliation":[{"name":"Pharmatest Services Ltd., 20520 Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9953-5755","authenticated-orcid":false,"given":"Matias","family":"Knuuttila","sequence":"additional","affiliation":[{"name":"Aurexel Life Sciences Ltd., 21240 Askainen, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Sj\u00f6holm","sequence":"additional","affiliation":[{"name":"Aurexel Life Sciences Ltd., 21240 Askainen, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Wilson","sequence":"additional","affiliation":[{"name":"Aurexel Life Sciences Ltd., 21240 Askainen, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esa","family":"Alhoniemi","sequence":"additional","affiliation":[{"name":"Inoi Oy, 20100 Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6670-1497","authenticated-orcid":false,"given":"Dominik","family":"Mumberg","sequence":"additional","affiliation":[{"name":"Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9393-6235","authenticated-orcid":false,"given":"Sanna-Maria","family":"K\u00e4k\u00f6nen","sequence":"additional","affiliation":[{"name":"Aurexel Life Sciences Ltd., 21240 Askainen, Finland"},{"name":"Institute of Biomedicine, University of Turku, 20520 Turku, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Scholz","sequence":"additional","affiliation":[{"name":"Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Suominen, M.I., Wilson, T., Kakonen, S.M., and Scholz, A. (2019). The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20163899"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"18489","DOI":"10.1038\/s41598-019-54884-7","article-title":"Radiobiological effects of the alpha emitter Ra-223 on tumor cells","volume":"9","author":"Bannik","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/COC.0000000000000528","article-title":"Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection","volume":"42","author":"Den","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102864","DOI":"10.1016\/j.critrevonc.2020.102864","article-title":"Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review","volume":"146","author":"Cursano","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.clgc.2017.10.022","article-title":"eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer","volume":"16","author":"Shore","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1200\/JCO.2019.37.15_suppl.5007","article-title":"Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333\/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis","volume":"37","author":"Tombal","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1200\/JCO.2021.39.15_suppl.5002","article-title":"Decreased fracture rate by mandating bone protecting agents in the EORTC 1333\/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis","volume":"39","author":"Gillessen","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.clgc.2022.04.015","article-title":"Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis","volume":"20","author":"Trieu","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41391-020-0236-0","article-title":"Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone\/prednisone: Real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer","volume":"23","author":"Shore","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"107.e1","DOI":"10.1016\/j.clgc.2022.09.002","article-title":"Real World Outcomes in Patients With Metastatic, Castration-Resistant Prostate Cancer Treated With Radium-223 in Routine Clinical Practice in Sweden","volume":"21","author":"Stattin","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1158\/1078-0432.CCR-16-2955","article-title":"Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models","volume":"23","author":"Suominen","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/jbmr.141","article-title":"Guidelines for assessment of bone microstructure in rodents using micro-computed tomography","volume":"25","author":"Bouxsein","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/978-1-61779-415-5_27","article-title":"Analysis of bone architecture in rodents using microcomputed tomography","volume":"816","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_18","unstructured":"John, P., Bilezikian, L.G.R., and John Martin, T. (2008). Principles of Bone Biology, Academic Press."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/978-1-61779-415-5_35","article-title":"Mechanical properties of bone ex vivo","volume":"816","author":"Goodyear","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/jbmr.2539","article-title":"Establishing biomechanical mechanisms in mouse models: Practical guidelines for systematically evaluating phenotypic changes in the diaphyses of long bones","volume":"30","author":"Jepsen","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_21","unstructured":"John, P., Bilezikian, L.G.R., and John Martin, T. (2008). Principles of Bone Biology, Academic Press. [3rd ed.]."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/8756-3282(94)90276-3","article-title":"The mechanical strength of bone in different rat models of experimental osteoporosis","volume":"15","author":"Peng","year":"1994","journal-title":"Bone"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/8756-3282(93)90081-K","article-title":"Basic biomechanical measurements of bone: A tutorial","volume":"14","author":"Turner","year":"1993","journal-title":"Bone"},{"key":"ref_24","unstructured":"John, P., Bilezikian, L.G.R., and John Martin, T. (2008). Principles of Bone Biology, Academic Press."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-1-61779-415-5_19","article-title":"Histomorphometry in rodents","volume":"816","author":"Erben","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"ref_27","unstructured":"R Core Team (2016). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(18)30929-X","article-title":"Combination therapies in prostate cancer: Proceed with caution","volume":"20","author":"Spratt","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"E456","DOI":"10.1210\/jc.2010-0902","article-title":"Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy","volume":"95","author":"Hamilton","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s00198-013-2343-4","article-title":"Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D","volume":"24","author":"Alibhai","year":"2013","journal-title":"Osteoporos. Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"Logothetis","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1200\/JCO.2019.37.7_suppl.237","article-title":"Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials","volume":"37","author":"TOMBAL","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Suominen, M.I., Knuuttila, M., Schatz, C.A., Schlicker, A., V\u00e4\u00e4r\u00e4niemi, J., Sj\u00f6holm, B., Alhoniemi, E., Haendler, B., Mumberg, D., and K\u00e4k\u00f6nen, S.M. (2023). Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032189"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0006-291X(05)80067-1","article-title":"A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens","volume":"173","author":"Veldscholte","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","article-title":"Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_36","first-page":"499","article-title":"Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption","volume":"52","author":"Halleen","year":"2006","journal-title":"Clin. Lab."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mikah, P., Krabbe, L.M., Eminaga, O., Herrmann, E., Papavassilis, P., Hinkelammert, R., Semjonow, A., Schrader, A.J., and Boegemann, M. (2016). Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2260-y"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1016\/S1470-2045(19)30226-8","article-title":"Early use of abiraterone and radium-223 in metastatic prostate cancer","volume":"20","author":"Cursano","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.eururo.2019.01.026","article-title":"Higher Risk of Fragility Fractures in Prostate Cancer Patients Treated with Combined Radium-223 and Abiraterone: Prednisone May Be the Culprit","volume":"75","author":"Formenti","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00223-012-9684-4","article-title":"Acute effects of glucocorticoids on serum markers of osteoclasts, osteoblasts, and osteocytes","volume":"92","author":"Pavelka","year":"2013","journal-title":"Calcif. Tissue Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1359\/JBMR.041125","article-title":"Effects of low-dose prednisone on bone metabolism","volume":"20","author":"Ton","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1210\/en.2003-0990","article-title":"Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength","volume":"145","author":"Jia","year":"2004","journal-title":"Endocrinology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00223-007-9101-6","article-title":"Short-term changes in serum PINP predict long-term changes in trabecular bone in the rat ovariectomy model","volume":"82","author":"Rissanen","year":"2008","journal-title":"Calcif. Tissue Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/jnci\/djt116","article-title":"Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis","volume":"105","author":"Suominen","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1080\/09553002.2020.1838655","article-title":"Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: A national multicenter study","volume":"96","author":"Frantellizzi","year":"2020","journal-title":"Int. J. Radiat. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1007\/s00259-020-04796-w","article-title":"Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223","volume":"47","author":"Caffo","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/16\/4115\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:34:15Z","timestamp":1760128455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/16\/4115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,15]]},"references-count":46,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["cancers15164115"],"URL":"https:\/\/doi.org\/10.3390\/cancers15164115","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,15]]}}}